Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Rollover Study of ARRY-371797 in Patients With Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation

NCT02351856 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02351856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02351856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Rollover Study of ARRY-371797 in Patients With Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
February 2, 2015
Completion date
December 21, 2020
Enrollment
8 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lmna-related dilated cardiomyopathy